Imagen de Google Jackets
Vista normal Vista MARC

Brain-disabling treatments in psychiatry : drugs, electroshock, and the psychopharmaceutical complex / Peter R. Breggin.

Por: Tipo de material: TextoTextoDetalles de publicación: New York : Springer Pub., 2008.Edición: 2nd edDescripción: xxx, 546 p. ; 24 cmISBN:
  • 9780826129345 (alk. paper)
  • 082612934X (alk. paper)
Tema(s): Clasificación LoC:
  • RC 483 B72.2008
Contenidos:
The brain-disabling, spellbinding effects of psychiatric drugs -- Deactivation syndrome (chemical lobotomy) caused by neuroleptics -- neuroleptic-induced anguish, including agitation, despair, and depression -- Severe and potentially irreversible neurological syndromes (tardive dyskinesia and neuroleptic malignant syndrome) caused by neuroleptics -- Neuroleptic-induced neurotoxicity, brain damage, persistent cognitive deficits, dementia, and psychosis -- Recent developments in antidepressant label changes -- Antidepressant-induced mental, behavioral, and cerebral abnormalities -- Lithium and other drugs for bipolar disorder -- Electroconvulsive therapy (ECT) for depression -- From attention-deficit/hyperactivity disorder (ADHD) to bipolar disorder : diagnosing America's children -- Stimulant-induced brain damage, brain dysfunction, and psychiatric adverse reactions -- Antianxiety drugs, including behavioral abnormalities caused by Xanax and Halcion -- The Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH) : drug company advocates -- Drug company deceptions -- How to more safely stop taking psychiatric drugs -- Failed promises, last resorts, and psychotherapy.
Valoración
    Valoración media: 0.0 (0 votos)
Existencias
Tipo de ítem Biblioteca actual Colección Signatura topográfica Copia número Estado Fecha de vencimiento Código de barras
Libros Biblioteca Francisco Xavier Clavigero Acervo Acervo General RC 483 B72.2008 (Navegar estantería(Abre debajo)) ej. 1 Disponible UIA026042

Incluye referencias bibliográficas (p. 463-526) e índice.

The brain-disabling, spellbinding effects of psychiatric drugs -- Deactivation syndrome (chemical lobotomy) caused by neuroleptics -- neuroleptic-induced anguish, including agitation, despair, and depression -- Severe and potentially irreversible neurological syndromes (tardive dyskinesia and neuroleptic malignant syndrome) caused by neuroleptics -- Neuroleptic-induced neurotoxicity, brain damage, persistent cognitive deficits, dementia, and psychosis -- Recent developments in antidepressant label changes -- Antidepressant-induced mental, behavioral, and cerebral abnormalities -- Lithium and other drugs for bipolar disorder -- Electroconvulsive therapy (ECT) for depression -- From attention-deficit/hyperactivity disorder (ADHD) to bipolar disorder : diagnosing America's children -- Stimulant-induced brain damage, brain dysfunction, and psychiatric adverse reactions -- Antianxiety drugs, including behavioral abnormalities caused by Xanax and Halcion -- The Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH) : drug company advocates -- Drug company deceptions -- How to more safely stop taking psychiatric drugs -- Failed promises, last resorts, and psychotherapy.